Rezolute (RZLT) Operating Leases (2019 - 2026)
Rezolute recorded quarterly Operating Leases of $438000.0 in Q1 2026, down 29.24% quarter-over-quarter from $619000.0 in Q4 2025, and down 62.24% year-over-year from $1.2 million in Q1 2025.
Rezolute's Operating Leases history runs 8 years deep, the most recent figure standing at $438000.0 for Q1 2026.
- In Q1 2026, Operating Leases fell 62.24% year-over-year to $438000.0; the TTM figure through Mar 2026 stood at $438000.0 (down 62.24% YoY), while the FY2025 annual figure was $983000.0, down 40.78% from the prior year.
- Operating Leases came in at $438000.0 for Q1 2026 at Rezolute, down from $619000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.2 million in Q4 2022 to a low of $49000.0 in Q3 2022.
- A 5-year average of $1.2 million and a median of $1.3 million in 2024 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases plunged 69.57% in 2022 and soared 3602.04% in 2023, its largest moves.
- Rezolute's Operating Leases stood at $2.2 million in 2022, then decreased by 10.06% to $2.0 million in 2023, then tumbled by 32.51% to $1.3 million in 2024, then slumped by 53.56% to $619000.0 in 2025, then slipped by 29.24% to $438000.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $438000.0, $619000.0, and $804000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 438,000.00 |
| Dec 31, 2025 | 619,000.00 |
| Sep 30, 2025 | 804,000.00 |
| Jun 30, 2025 | 983,000.00 |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 80,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Sep 30, 2021 | 161,000.00 |
| Jun 30, 2021 | 187,000.00 |
| Mar 31, 2021 | 213,000.00 |
| Dec 31, 2020 | 281,000.00 |
| Sep 30, 2020 | 104,000.00 |
| Jun 30, 2020 | 165,000.00 |
| Mar 31, 2020 | 224,000.00 |
| Dec 31, 2019 | 287,000.00 |
| Sep 30, 2019 | 346,000.00 |